Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus nab-paclitaxel and gemcitabine as first-line treatment for advanced pancreatic ductal adenocarcinoma
ChiCTR2000032293Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Overall survival and Safety. Planned start May 2020; status: not yet recruiting.
02
Drugs
toripalimabpaclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2000032293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032293.